REYATAZ

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Estonia, Spain, France, Hong Kong, Croatia, Ireland, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, United Kingdom, United States, South Africa

Active ingredients

The drug REYATAZ contains one active pharmaceutical ingredient (API):

1 Atazanavir UNII 4MT4VIE29P - ATAZANAVIR SULFATE

Atazanavir is an azapeptide HIV-1 protease inhibitor (PI). The compound selectively inhibits the virus-specific processing of viral Gag-Pol proteins in HIV-1 infected cells, thus preventing formation of mature virions and infection of other cells. Read about Atazanavir

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
REYATAZ Hard capsule	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J05AE08	Atazanavir	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AE Protease inhibitors
Discover more medicines within J05AE08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 10321F, 10349Q
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 505107902111212, 505107903116315
Country: CA	Health Products and Food Branch	Identifier(s): 02248610, 02248611, 02294176
Country: EE	Ravimiamet	Identifier(s): 1208168, 1208179, 1208180, 1208191, 1368086, 1402489, 1722495, 1722507
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 03267004, 03267006, 03267008
Country: FR	Base de données publique des médicaments	Identifier(s): 66745660, 68301348, 69443966
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 136417, 73374, 73377
Country: HK	Department of Health Drug Office	Identifier(s): 52846, 56784
Country: IT	Agenzia del Farmaco	Identifier(s): 036196018, 036196020, 036196032, 036196044, 036196057, 036196069, 036196071, 036196083, 036196095, 036196107, 036196119, 036196121
Country: JP	医薬品医療機器総合機構	Identifier(s): 6250023M1026, 6250023M2022
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1030704, 1030705, 1030706, 1030707, 1030708, 1030709, 1032112, 1032113, 1056564, 1080849, 1080850
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 74330, 74349, 86479
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 11007, 11008, 13160
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100125810, 100125827, 100125833, 100193409, 100398726
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W65567001, W65567002, W65568001, W65568002, W65569001, W65569002, W65569003
Country: SG	Health Sciences Authority	Identifier(s): 12520P, 12521P, 13560P
Country: US	FDA, National Drug Code	Identifier(s): 0003-3622, 0003-3624, 0003-3631, 0003-3638, 67296-1236
Country: ZA	Health Products Regulatory Authority	Identifier(s): A39/20.2.8/0088, A39/20.2.8/0089